Sanjay Chanda
Chief Development Officer · AN2 Therapeutics, Inc.
- 2026
- Mar 23, 2026
- 3
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Sanjay Chanda files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Robin Shane Readnour - $317K in ANTX purchases and sales in the last 12 months
- Joshua M. Eizen - $53K in ANTX purchases and sales in the last 12 months
- Margaret M. Fitzpatrick - $12K in ANTX purchases and sales in the last 12 months
- Lucy Day - $9K in ANTX purchases and sales in the last 12 months
- Stephen David Prior - $7K in ANTX purchases and sales in the last 12 months
- Sarah Joanne Williams - $3K in ANTX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Sanjay Chanda?
Sanjay Chanda is a corporate insider, tracked as Chief Development Officer of AN2 Therapeutics, Inc. (ANTX). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Sanjay Chanda last file a Form 4?
The most recent primary Form 4 on record is dated 23 March 2026, one of 3 filings going back to 2026.
Has Sanjay Chanda been buying or selling stock?
Recorded transactions: 0 open-market purchases and 2 open-market sales ($9K) across all tracked filings.
